Dextromoramide

Summary

Dextromoramide (CHEMBL3833389) is an approved small molecule (ATC N02AC01); indicated across 1 condition.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N02AC01
• Indications: 1 condition
• Chemistry: 392.5 Da · C25H32N2O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3833389
Name	Dextromoramide
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	127021145
ATC	N02AC01
Molecular formula	C25H32N2O2
Molecular weight	392.5
InChIKey	XHKXWINHANRSNT-NRFANRHFSA-N

SMILES: C[C@@H](CC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)N3CCCC3)N4CCOCC4

IUPAC name: (4S)-4-morpholin-4-yl-2,2-diphenyl-1-pyrrolidin-1-ylpentan-1-one

Also known as: Acscn-9613, Alcoid, Dextromoramida, Dextromoramide, IDS-ND-003, Jetrium, Linfadol, MCP-875, Moramide, Narcolo, Palfadonna, R-875

Parent form; salt/anhydrous children: CHEMBL3833311

Patent coverage: 18 distinct patent families (18 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).